NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 5 நாட்களுக்கு முன்இன்று 1320 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Divi's Lab Q2 FY27 Consolidated PAT Surges 63.6% YoY to ₹1,127 Cr; Revenue at ₹3,770 Cr
Divi's Laboratories reported strong Q2 FY27 results, with consolidated total income increasing 31.8% YoY to ₹3,770 crore compared to ₹2,860 crore in Q2 FY26. Consolidated profit after tax (PAT) jumped 63.6% YoY to ₹1,127 crore from ₹689 crore in the corresponding period of the previous year. On a standalone basis, revenue from operations reached ₹3,647 crore, driven by robust performance across its active pharmaceutical ingredient and custom synthesis segments. Basic EPS on a standalone basis increased to ₹42.97 for the quarter, up from ₹26.24 in Q2 FY26.
உச்சம் நம்பிக்கை
என்ன மாறியதுDivi's reported its financial performance for Q2 ended September 30, 2026, delivering substantial YoY acceleration in revenue and profit.
ஏன் இது முக்கியம்Demonstrates continued margin recovery and strong top-line momentum in high-value custom synthesis and API businesses, supporting the company's valuation base.
Consolidated Total Income (Q2): ₹3770 கோடிConsolidated PAT (Q2): ₹1127 கோடிStandalone Revenue from Operations (Q2): ₹3647 கோடிStandalone Basic EPS (Q2): Rs. 42.97
📅 குறுகிய காலம்The market is likely to react positively to the strong 63.6% YoY PAT growth and sequential margin stability.
📈 நீண்ட காலம்Continued operational leverage and scaling of newer manufacturing capacities support sustained medium-to-long term earnings visibility in custom synthesis.
⚠ அபாய எச்சரிக்கைகள்
High working capital lock-in, with standalone inventories rising to ₹5,325 crore as of September 30, 2026
Export and client concentration risks characteristic of major API/CRAMS contracts
👀 கவனிக்க வேண்டியவை
Track management commentary on custom synthesis demand and capacity utilization at the Kakinada facility in upcoming investor calls.
Divi's Labs Q1 FY27: ₹500 Cr Inventory Surge and Progress on 3 Major Capex Projects
Divi's Laboratories reported stable volumes in its generic business for Q1 FY27, though pricing remains competitive due to market conditions. A significant ₹500 crore inventory increase was recorded this quarter, far exceeding the usual ₹50-100 crore run rate, driven by validation projects and higher solvent costs. Three major capex programs are nearing completion and entering the validation phase, which is critical for future commercial supply. The company is also scaling its peptide synthesis capabilities and its nutraceutical portfolio, which now exceeds 100 offerings.
உச்சம் நம்பிக்கை
என்ன மாறியதுThis filing provides the detailed transcript of the Q1 FY27 earnings call, clarifying the reasons behind inventory fluctuations and the status of major infrastructure projects.
ஏன் இது முக்கியம்The transcript reveals that margin pressure is linked to elevated solvent costs and a strategic inventory buildup for validation batches, which are precursors to commercial revenue from new molecules.
📅 குறுகிய காலம்The stock may see neutral to cautious sentiment as investors digest the impact of high solvent costs and the large inventory buildup on immediate cash flows.
📈 நீண்ட காலம்Structural growth remains tied to the successful ramp-up of the Kakinada plant (Unit 3) and the commercialization of the Custom Synthesis and Peptide pipelines.
⚠ அபாய எச்சரிக்கைகள்
Elevated solvent costs
Geopolitical uncertainty in West Asia affecting supply chains
Revenue concentration in top 5 products
👀 கவனிக்க வேண்டியவை
Monitor the commercialization timeline of the three major capex projects and the stabilization of solvent prices, which management identified as a margin headwind.
Divi's Laboratories reported a strong start to FY27 with consolidated revenue growing 27.8% YoY to Rs 3,080 Cr. Net profit surged 65.5% YoY to Rs 902 Cr, significantly outpacing revenue growth despite a forex loss of Rs 7 Cr. The Board also elevated two veterans, Mr. B. Vara Prasad and Mr. J. Srinivasa Rao (both with 30+ years at the firm), to Senior Management roles to oversee Engineering and Raw Material procurement. The results reflect robust operational performance with Profit Before Tax (PBT) rising 61% YoY to Rs 1,180 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுDivi's Labs reported its Q1 FY27 financial results showing substantial profit growth and formalized the promotion of two internal procurement heads to the Senior Management team.
ஏன் இது முக்கியம்The significant profit growth indicates strong operational leverage and potentially a higher contribution from the high-margin Custom Synthesis segment. Internal promotions in supply chain management reinforce the company's focus on procurement efficiency and sustainable sourcing.
Consolidated Revenue (Q1 FY27): Rs 3,080 கோடிConsolidated PAT (Q1 FY27): Rs 902 கோடிYoY PAT Growth: 65.5%Q1 வருவாய் vs TTM வருவாய்: 29.2%Forex Loss: Rs 7 கோடி
📅 குறுகிய காலம்The stock is likely to react positively to the strong earnings beat and significant margin expansion compared to the previous year.
📈 நீண்ட காலம்Long-term growth is supported by capacity expansion at Kakinada and a strong position in the global CRAMS market, though high P/E (83.3) necessitates sustained high growth.
⚠ அபாய எச்சரிக்கைகள்
High revenue concentration in top five products
90% export dependency makes it sensitive to USFDA regulatory actions
Forex volatility impacting bottom line
👀 கவனிக்க வேண்டியவை
Investors should monitor the operationalization of the Kakinada plant scheduled for H2 FY25 and its contribution to volume growth. Watch for the company's progress in reducing product concentration risk (currently aiming for <30% for top 5 products) and maintaining OPM above 30%.
₹30 Dividend: Divi's Labs Sets August 10 for AGM and July 24 as Record Date
Divi's Laboratories has issued the notice for its 36th Annual General Meeting (AGM) scheduled for August 10, 2026. The company has recommended a final dividend of ₹30 per equity share (1,500% of face value) for FY26, which is subject to shareholder approval at the meeting. The record date for determining dividend eligibility is July 24, 2026, with payments expected to begin on August 14, 2026. This follows a year where the company reported a TTM PAT of ₹2,568 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formalized the schedule for its annual shareholder meeting and established the timeline for its FY26 dividend payout.
ஏன் இது முக்கியம்This is a routine but significant event for shareholders as it confirms the cash return for the fiscal year and provides a platform for management to discuss the company's strategic progress in CRAMS and API segments.
Dividend per share: ₹30Dividend % of Face Value: 1,500%ரெக்கார்ட் தேதி: ஜூலை 24, 2026AGM Date: ஆகஸ்ட் 10, 2026Dividend Yield (at current price): 0.41%
📅 குறுகிய காலம்The stock may see minor price adjustments around the ex-dividend date (typically one day before the record date).
📈 நீண்ட காலம்Limited structural significance as this is a routine annual administrative and dividend-related filing.
👀 கவனிக்க வேண்டியவை
Investors should ensure their bank details and PAN are updated with their Depository Participant by July 24, 2026, to receive the dividend. Watch for management commentary during the AGM regarding the operationalization of the Kakinada plant.
Divi's Labs FY26 PAT Rises 17% to ₹2,568 Cr; Capitalizes ₹1,544 Cr in Assets
Divi's Laboratories reported a robust performance for FY26, with total income reaching ₹11,067 crores, a 14% increase over the previous year. The company maintained a strong product mix with Custom Synthesis (CS) contributing 55% and Generics 45% of revenue. Despite geopolitical tensions affecting logistics in Q4, Divi's capitalized assets worth ₹1,544 crores during the year, including ₹800 crores in the final quarter, signaling significant capacity expansion. The company also reported an improved material consumption rate of 38.8% and a healthy cash position of ₹3,414 crores.
முக்கிய அம்சங்கள்
FY26 Consolidated Total Income grew to ₹11,067 crores from ₹9,712 crores in FY25.Custom Synthesis segment contributed 55% of total revenue, reflecting a high-value product mix.Capitalized assets worth ₹1,544 crores in FY26, with significant focus on Unit 3 and backward integration.One-time exceptional item of ₹74 crores provided for the implementation of new Labour Codes.Nutraceuticals business showed strong growth, reaching ₹946 crores compared to ₹781 crores YoY.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's aggressive capitalization and the ramp-up of Unit 3, which are expected to drive future growth. The increasing contribution of Custom Synthesis and the entry into the peptide segment provide high-margin long-term visibility.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Divi's Laboratories reported a strong performance for FY26, with annual revenue growing 13% to ₹10,388 crore and PAT increasing 18% to ₹2,607 crore. The company recommended a final dividend of ₹30 per share, reflecting a payout of 1,500% on face value. Despite a one-time exceptional charge of ₹74 crore related to new labour codes, margins remained resilient. Significant capital expenditure is evident with Capital Work-in-Progress doubling to ₹2,113 crore, indicating aggressive future capacity expansion.
முக்கிய அம்சங்கள்
Annual Revenue from operations grew by 13% YoY to ₹10,388 crore in FY26.Net Profit (PAT) for the full year rose 18% to ₹2,607 crore compared to ₹2,209 crore in FY25.Board recommended a final dividend of ₹30 per equity share (1,500% of face value) with a record date of July 24, 2026.Capital Work-in-Progress (CWIP) surged to ₹2,113 crore from ₹1,022 crore, signaling massive capacity expansion.Net cash inflow from operating activities improved significantly to ₹2,711 crore from ₹1,650 crore in the previous year.
👀 கவனிக்க வேண்டியவை
Investors should view the strong revenue growth and the doubling of CWIP as positive indicators for long-term scale-up. The healthy dividend payout and robust cash flow generation reinforce the company's strong fundamental position in the API sector.
Divi's Labs FY26 PAT Rises 18% to ₹2,607 Cr; Recommends ₹30 Final Dividend
Divi's Laboratories reported a robust performance for FY26, with annual revenue from operations growing 13% to ₹10,388 crore compared to ₹9,198 crore in FY25. Net profit for the year increased by 18% to ₹2,607 crore, even after accounting for a one-time exceptional charge of ₹74 crore related to new Labour Codes. The Board has recommended a significant final dividend of ₹30 per share (1,500% of face value), with the record date set for July 24, 2026. The company's balance sheet remains strong with a substantial increase in Capital Work-in-Progress to ₹2,113 crore, signaling aggressive future expansion.
முக்கிய அம்சங்கள்
Annual Revenue from operations increased 13% YoY to ₹10,388 crore in FY26.Net Profit (PAT) for the full year rose to ₹2,607 crore from ₹2,209 crore in FY25.Recommended a final dividend of ₹30 per equity share of face value ₹2 each.Exceptional item of ₹74 crore recognized due to the impact of new Labour Codes on employee benefits.Capital Work-in-Progress (CWIP) stood at ₹2,113 crore as of March 31, 2026, vs ₹1,022 crore YoY.
👀 கவனிக்க வேண்டியவை
The strong earnings growth and high dividend payout reflect healthy operational cash flows and management confidence. Long-term investors should monitor the conversion of the high CWIP into operational revenue as a key growth catalyst.
Divi's Labs Receives ₹570.51 Crore Income Tax Draft Order for FY2022-23
Divi's Laboratories has received a Draft Assessment Order for FY2022-23 (AY 2023-24) from the Income Tax Authority. The order proposes additions and disallowances totaling ₹570.51 crores to the company's returned income. These adjustments are primarily attributed to Transfer Pricing on specified domestic transactions and other corporate tax matters. The company intends to contest the order and file an appeal with the appropriate authorities.
முக்கிய அம்சங்கள்
Draft Order issued under Section 144C(1) of the Income Tax Act for FY2022-23.Proposed additions and disallowances amount to ₹570.51 crores.Adjustments involve Transfer Pricing on domestic transactions and corporate tax adjustments.Penalty proceedings under Section 270A for alleged under-reporting of income to be initiated separately.Company is evaluating the order and plans to file an appeal within the stipulated time.
👀 கவனிக்க வேண்டியவை
Investors should monitor the litigation progress as the proposed amount is significant, though it is currently a draft order and will likely be contested in higher tax forums. No immediate financial impact is expected until the final order is passed and appeals are exhausted.
Divi's Labs Q3FY26: Total Income Up 12% to ₹2,692 Cr; PAT Stable at ₹583 Cr Post-Exceptional Item
Divi's Laboratories reported a 12% year-on-year increase in total income to ₹2,692 crores for Q3FY26, driven by strong performance in Custom Synthesis and Nutraceuticals. While Profit Before Tax (pre-exceptional) grew to ₹854 crores, the bottom line was impacted by a one-time ₹74 crore exceptional charge related to new government labor codes. The company continues to shift its mix toward Custom Synthesis, which now accounts for 57% of revenue. Management confirmed that GLP-1 pilot and commercial blocks are completed and currently undergoing validation.
முக்கிய அம்சங்கள்
Total income for Q3FY26 rose to ₹2,692 crores from ₹2,401 crores in the previous year.Custom Synthesis segment contributed 57% of revenue, while Generics accounted for 43%.Material consumption costs improved to 36.3% of sales, down from 39.8% in Q3FY25.Exceptional item of ₹74 crores recognized due to revised employee benefit obligations under new labor codes.Capital work in progress (CWIP) remains high at ₹2,394 crores, focusing on GLP-1 capacity and Unit 3 expansions.
👀 கவனிக்க வேண்டியவை
Investors should focus on the improving gross margins and the progress in the high-growth GLP-1/Peptide segment which is nearing commercialization. The one-time exceptional hit is non-recurring, and the underlying operational strength remains robust with a successful US FDA inspection at Unit 1.
Divi's Labs Q3 FY26 Consolidated Revenue up 12% YoY to ₹2,604 Cr; PAT Flat at ₹583 Cr
Divi's Laboratories reported a 12.3% YoY growth in consolidated revenue at ₹2,604 crore for Q3 FY26. However, consolidated net profit remained nearly flat at ₹583 crore, compared to ₹589 crore in the previous year, primarily due to a one-time exceptional charge of ₹74 crore related to new Labour Codes. On a sequential basis, revenue and PAT declined by 4.1% and 15.4% respectively. Despite the flat PAT, the 9-month consolidated profit shows a healthy 18.8% growth YoY reaching ₹1,817 crore.
முக்கிய அம்சங்கள்
Consolidated Revenue from operations grew 12.3% YoY to ₹2,604 crore.Consolidated Net Profit stood at ₹583 crore, down 1% YoY, impacted by a ₹74 crore exceptional item.Profit Before Tax (before exceptional items) increased 17.6% YoY to ₹854 crore.Nine-month (9M FY26) consolidated PAT grew 18.8% YoY to ₹1,817 crore.Forex gain for the quarter was significantly lower at ₹18 crore compared to ₹64 crore in the previous quarter.
👀 கவனிக்க வேண்டியவை
Investors should look past the one-time exceptional labour code impact and focus on the steady 12% top-line growth. While sequential performance was soft, the 9-month growth trajectory remains positive for long-term holders.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
